As per Washington state guidance, masks are required regardless of vaccination status in all of our facilities. Please be aware that if you do not have a mask when you arrive we can provide one for you or reschedule your appointment. We appreciate your understanding!

Arena Pharmaceuticals

Placebo-Controlled, 52 week Study to assess the efficacy and safety of Etrasimod in subjects with moderately to severely active UC.

  • Etrasimod is an orally administered, selective, synthetic sphingosine 1-pjhospahte receptor (SIP)
  • Males and females 16-80 with a diagnosis of moderately to severely active UC.
  • Must have failed or had inadequate response to: 5-ASAs. Steroids, biologics or JAK 1s.
  • Open-label extension following end of study

If you are interested in participating in clinical studies, please send an email to wagiresearch@washgi.com.

17 Locations Focused on Serving Your Needs

Email us at [email protected]